The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 120 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] Ness-Abramof, 2002, Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese., Obes Res sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] Smith, 1996, Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues., J Clin Endocrinol Metab source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] Pecori Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series., J Clin Endocrinol Metab source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] Batista, 2007, Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 201–300 of 2,716
The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality
Limumpornpetch, P., Morgan, A. W., Tiganescu, A., Baxter, P. D., Nyawira Nyaga, V., Pujades-Rodriguez, M., & Stewart, P. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac265 · Cited by 87
Self-citationAdvances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications
Arnaldi, G., Mancini, T., Tirabassi, G., Trementino, L., & Boscaro, M. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03345431 · Cited by 93
“This problem is one of the most discriminating elements characterizing CS (96) and its prevalence varies between 40 and 80% in patients with endogenous CS (97-99).”
Brue, T., Amodru, V., & Castinetti, F. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-1058 · Cited by 85
Recent Updates on the Diagnosis and Management of Cushing's Syndrome
Nieman, L. K. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.139 · Cited by 85
Self-citationBertherat, J. Y., Bourdeau, I., Bouys, L., Chasseloup, F., Kamenický, P., & Lacroix, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac034 · Cited by 100
López, J. P., Brivio, E., Santambrogio, A., Donno, C. D., Kos, A., Peters, M., Rost, N., Czamara, D., Brückl, T. M., Roeh, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe4497 · Cited by 97
Carrasco, C. A., Coste, J., Guignat, L., Groussin, L., Dugué, M. A., Gaillard, S., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1171 · Cited by 83
Honour, J. W. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217739930 · Cited by 99
Di Dalmazi, G., Fanelli, F., Mezzullo, M., Casadio, E., Rinaldi, E., Garelli, S., Giampalma, E., Mosconi, C., Golfieri, R., Vicennati, V., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1992 · Cited by 82
“This cut-off was chosen to maximize the sensitivity of DST, in analogy with the screening of Cushing’s syndrome, according to the current guidelines (2, 4, 14, 15).”
MethodApproach to androgen excess in women: Clinical and biochemical insights
Cussen, L., McDonnell, T., Bennett, G., Thompson, C. J., Sherlock, M., & O’Reilly, M. (2022) · Clinical Endocrinology · doi:10.1111/cen.14710 · Cited by 110
“Discriminant clinical features of hypercortisolism include violaceous abdominal striae and proximal muscle weakness; the presence of suppressed gonadotropins and oestradiol, bruising, osteoporosis and hypertension should also raise the index of suspicion.(57) Serum levels of DHEAS and A4 may be elevated due to autonom…”
BackgroundHypertension: The role of biochemistry in the diagnosis and management
O’Shea, P. M., Griffin, T. P., & Fitzgibbon, M. C. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.12.014 · Cited by 103
Cortisol measurements in Cushing’s syndrome: immunoassay or mass spectrometry?
Casals, G., & Hanzu, F. A. (2020) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.4.285 · Cited by 80
Deutschbein, T., Broecker-Preuss, M., Flitsch, J., Jaeger, A., Althoff, R., Walz, M. K., Mann, K., & Petersenn, S. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0945 · Cited by 81
Toward a Diagnostic Score in Cushing's Syndrome
Braun, L. T., Riester, A., Oßwald-Kopp, A., Fazel, J., Rubinstein, G., Bidlingmaier, M., Beuschlein, F., & Reincke, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00766 · Cited by 81
“The US Endocrine Society Practice guideline (66) recommends three tests for biochemical screening: the 1-mg LDDST, the 24-h urine cortisol (UFC) determination, and the latenight salivary cortisol measurement.”
BackgroundInfluentialScreening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS
Ceccato, F., Barbot, M., Zilio, M., Frigo, A. C., Albiger, N., Camozzi, V., Antonelli, G., Plebani, M., Mantero, F., Boscaro, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2507 · Cited by 82
“To avoid possible interferences (1), records were reviewed for medications (by F.”
BackgroundMethodInfluentialMALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation
Calligaris, D., Feldman, D. R., Norton, I. H., Olubiyi, O. I., Changelian, A. N., Machaidze, R., Vestal, M. L., Laws, E. R., Dunn, I. F., Santagata, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423101112 · Cited by 81
Principles and pitfalls of free hormone measurements
Faix, J. D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.06.007 · Cited by 92
Dennedy, M. C., Annamalai, A. K., Prankerd Smith, O., Freeman, N., Vengopal, K., Graggaber, J., Koulouri, O., Powlson, A. S., Shaw, A., Halsall, D. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2718 · Cited by 81
“0 mcg/dL (83 nmol/L)] as a confirmatory test for SH, we have used the diagnostic criteria recommended in the Endocrine Society Clinical Practice Guidelines (4), which include the LDDST as a “gold-standard” confirmatory test.”
BackgroundMethodInfluentialSubclinical hyperfunctioning pituitary adenomas: The silent tumors
Cooper, O. B., & Melmed, S. K. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.01.002 · Cited by 83
Diagnosis and management of primary bilateral macronodular adrenal hyperplasia
Vassiliadi, D. A., & Tsagarakis, S. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0240 · Cited by 87
Janković, D., Wolf, P. S., Anderwald, C. H., Winhofer, Y., Promintzer‐Schifferl, M., Hofer, A., Langer, F. B., Prager, G., Ludvik, B. H., Gessl, A., et al. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0545-4 · Cited by 86
“In case of insufficient dexamethasone-induced suppression of serum cortisol concentrations (>3 μg/dl), patients were reinvestigated according to current guidelines [19]: In a standard Liddle 48-h 2-mg/day DST, 0.”
MethodPolluted Pathways: Mechanisms of Metabolic Disruption by Endocrine Disrupting Chemicals
Mimoto, M. S., Nadal, A., & Sargis, R. M. (2017) · Current Environmental Health Reports · doi:10.1007/s40572-017-0137-0 · Cited by 80
Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism?
Giordano, C., Guarnotta, V., Pivonello, R., Amato, M. C., Simeoli, C., Ciresi, A., Cozzolino, A., & Colao, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0754 · Cited by 79
Wasserman, J. D., Tomlinson, G. E., Druker, H. A., Kamihara, J., Kohlmann, W. K., Kratz, C. P., Nathanson, K. L., Pajtler, K. W., Parareda, A., Rednam, S. P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0548 · Cited by 81
SIMBA: using Kolb’s learning theory in simulation-based learning to improve participants’ confidence
Davitadze, M., Ooi, E., Ng, C. Y., Zhou, D., Thomas, L., Hanania, T., Blaggan, P., Evans, N., Chen, W., Melson, E., et al. (2022) · BMC Medical Education · doi:10.1186/s12909-022-03176-2 · Cited by 107
Adrenal diseases during pregnancy: pathophysiology, diagnosis and management strategies
Kamoun, M., Mnif, M. F., Charfi, N., Kacem, F. H., Naceur, B. B., Mnif, F., Dammak, M., Rekik, N., & Abid, M. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828aaeee · Cited by 77
“The best screening test in pregnancy is a 24-hour urine collection for free cortisol.(25) Lindsay et al(20) have proposed that, during the second and third trimesters of gestation, UFC concentrations greater than 3 times the upper normal limit can be considered to be consistent with pathological hypercortisolism.”
BackgroundValassi, E., Swearingen, B., Lee, H., Nachtigall, L. B., Donoho, D. A., Klibanski, A., & Biller, B. M. K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1500 · Cited by 78
“Its efficacy can be affected by several variables, including dexamethasone compliance, the type of CRH used, and patient comorbidities (2).”
BackgroundMethodInfluentialSelf-citationThe Evaluation of Incidentally Discovered Adrenal Masses
Vaidya, A., Hamrahian, A., Bancos, I., Fleseriu, M., & Ghayee, H. K. (2019) · Endocrine Practice · doi:10.4158/dscr-2018-0565 · Cited by 78
Adrenal incidentaloma: a diagnostic challenge
Anagnostis, P. G., Karagiannis, A. I., Τζιόμαλος, Κ., Kakafika, A. I., Athyros, V. G., & Mikhailidis, D. P. (2009) · HORMONES · doi:10.14310/horm.2002.1233 · Cited by 96
“either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test.(59) Recent”
BackgroundCrona, J., Norlén, O., Antonodimitrakis, P. C., Welin, S., Stalberg, P. L. H., & Eriksson, B. K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2436 · Cited by 86
“no suppression of cortisol and ACTH after a 1-mg overnight dexamethasone suppression test (19).”
BackgroundCeccato, F., Barbot, M., Zilio, M., Ferasin, S., Occhi, G., Daniele, A., Mazzocut, S., Iacobone, M., Betterle, C., Mantero, F., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0159 · Cited by 75
Sahakitrungruang, T., Srichomthong, C., Pornkunwilai, S., Amornfa, J., Shuangshoti, S., Kulawonganunchai, S., Suphapeetiporn, K., & Shotelersuk, V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1016 · Cited by 78
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS
Lim, C. T., & Korbonits, M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0034 · Cited by 86
Autonomous cortisol secretion in adrenal incidentalomas
Castro, M. A., Núñez, M. A. S., & Marazuela, M. (2019) · Endocrine · doi:10.1007/s12020-019-01888-y · Cited by 85
Pivonello, R., Bancos, I., Feelders, R. A., Kargi, A. Y., Kerr, J. M., Gordon, M. B., Mariash, C. N., Terzolo, M., Ellison, N., & Moraitis, A. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.662865 · Cited by 87
“7 nmol/L]) on either the overnight 1-mg or 48-h 2-mg dexamethasone suppression test (DST) (1, 21).”
BackgroundInfluentialLonser, R. R., Ksendzovsky, A., Wind, J. J., et al. (2011) · Journal of neurosurgery · doi:10.3171/2011.8.jns11456 · Cited by 75
“6–10 31 (36) 4 (13) 3 (10) 2 (6) 9 (29)”
Cooper, O. B. (2014) · Pituitary · doi:10.1007/s11102-014-0624-3 · Cited by 75
Ceccato, F., Artusi, C., Barbot, M., Lizzul, L., Pinelli, S., Costantini, G., Niero, S., Antonelli, G., Plebani, M., & Scaroni, C. M. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01197-6 · Cited by 79
A clinical perspective on ectopic Cushing’s syndrome
Ragnarsson, Ó., Juhlin, C. C., Torpy, D. J., & Falhammar, H. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.12.003 · Cited by 95
Belaya, Z. E., Hans, D. B., Rozhinskaya, L. Y., Dragunova, N. V., Sasonova, N. I., Solodovnikov, A. G., Тамерланович, Ц. Т., Dzeranova, L. K., Mel'nichenko, G. A., & Dedov, I. I. (2015) · Archives of Osteoporosis · doi:10.1007/s11657-015-0244-1 · Cited by 81
“ACTH production from tumor outside the pituitary, or autonomous adrenal overproduction [1].”
BackgroundMethodInfluentialRaff, H. (2013) · Endocrine · doi:10.1007/s12020-013-0013-0 · Cited by 72
Eller-Vainicher, C., Morelli, V., Salcuni, A. S., Battista, C., Torlontano, M., Coletti, F., Iorio, L., Cairoli, E., Beck-Peccoz, P., Arosio, M., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0602 · Cited by 73
Systematic review of surgical treatment of subclinical Cushing's syndrome
Iacobone, M., Citton, M., Scarpa, M., Viel, G., Boscaro, M., & Nitti, D. (2015) · British Journal of Surgery · doi:10.1002/bjs.9742 · Cited by 72
Nonfunctioning pituitary tumors
Molitch, M. E. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00012-5 · Cited by 73
“The best screening tests for Cushing’s syndrome have traditionally been the overnight dexamethasone suppression test and the 24 hour urinary free cortisol and, more recently, the assessment of a midnight salivary cortisol (Findling and Raff, 2006; Carroll et al., 2008; Nieman et al., 2008).”
BackgroundPeng, K., Liao, H., Chan, C., Lin, W., Yang, S., Tsai, Y., Huang, K., Lin, Y., Chueh, S., & Wu, V. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15328 · Cited by 76
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease
Liu, N.-A., Araki, T., Cuevas-Ramos, D., Hong, J., Ben-Shlomo, A., Tone, Y., Tone, M., & Melmed, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1606 · Cited by 71
Xu, Y., Rui, W., Qi, Y., Zhang, C., Zhao, J., Wang, X., Wu, Y., Zhu, Q., Shen, Z., Ning, G., et al. (2013) · World Journal of Surgery · doi:10.1007/s00268-013-2059-9 · Cited by 71
“As a result of autonomous primary adrenal pathology producing cortisol, ACTH-independent CS accounts for 15–20 % of endogenous CS, and most cases result from unilateral adrenal adenoma or carcinoma [8].”
BackgroundBednarczuk, T., Bolanowski, M., Sworczak, K., Górnicka, B., Cieszanowski, A., Otto, M., Ambroziak, U., Pachucki, J., Kubicka, E., Babińska, A., et al. (2016) · Endokrynologia Polska · doi:10.5603/ep.a2016.0039 · Cited by 94
“PO D YP LO M O W E the upper limit established for a given laboratory indicates Cushing’s syndrome [17].”
BackgroundCushing’s Syndrome: Screening and Diagnosis
Ceccato, F., & Boscaro, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0153-4 · Cited by 70
“Medication may impair dexamethasone metabolism, causing falsely abnormal results [1, 17]: dexamethasone is metabolized by the CYP3A4 complex, which is Fig.”
BackgroundInfluentialEvaluation of the Hypothalamic-Pituitary-Adrenal Axis Function in Childhood and Adolescence
Chrousos, G. P., Kino, T., & Charmandari, E. (2009) · Neuroimmunomodulation · doi:10.1159/000216185 · Cited by 70
Creemers, S. G., Feelders, R. A., de Jong, F. H., Franssen, G. J. H., de Rijke, Y. B., van Koetsveld, P. M., & Hofland, L. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00217 · Cited by 70
Popoviciu, M. S., Păduraru, L., Nutas, R. M., Ujoc, A. M., Yahya, G., Metwally, K. A., & Cavalu, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612676 · Cited by 106
Lopes, L. M. L., Francisco, R. P. V., Galletta, M. A. K., & Bronstein, M. D. (2016) · Pituitary · doi:10.1007/s11102-015-0680-3 · Cited by 70
“Among the first-line tests, LDDST should not be considered the first choice in pregnant women due to false positive results during pregnancy, a consequence of impaired response to dexamethasone [7].”
BackgroundNakajima, Y., Yamada, M., Taguchi, R., Satoh, T., Hashimoto, K., Ozawa, A., Shibusawa, N., Okada, S., Monden, T., & Mori, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2743 · Cited by 75
“However, for patients with adrenal incidentaloma, use of the urine cortisol level is not recommended due to the sensitivity of the evaluation of mild hypercortisolism (20, 21).”
BackgroundPregnancy and pituitary disorders: Challenges in diagnosis and management
Laway, B., & Mir, S. A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.122608 · Cited by 76
“[51] Adrenal etiology is the commonest cause of CS followed by pituitary and less commonly an ectopic tumor.[52] Biochemical evaluation of CS during pregnancy is complicated, because estrogen-induced production of cortisol binding globulin (CBG) coupled with increase in placental production of ACTH and CRH lead to inc…”
Persistence of myopathy in Cushing’s syndrome: evaluation of the German Cushing’s Registry
Berr, C. M., Stieg, M. R., Deutschbein, T., Quinkler, M., Schmidmaier, R., Osswald, A., Reisch, N., Ritzel, K., Dimopoulou, C., Fazel, J., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0689 · Cited by 70
How does obesity affect the endocrine system? A narrative review
Poddar, M., Chetty, Y., & Chetty, V. T. (2017) · Clinical Obesity · doi:10.1111/cob.12184 · Cited by 86
“dorsocervical fat pad, supraclavicular fossa and temporal areas (27,28,31,32).”
BackgroundInfluentialManetti, L., Rossi, G., Grasso, L., Raffaelli, V., Scattina, I., Del Sarto, S., Cosottini, M., Iannelli, A., Gasperi, M., Bogazzi, F., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0685 · Cited by 69
Lila, A. R., Gopal, R. A., Acharya, S. V., George, J., Sarathi, V., Bandgar, T., Menon, P. S., & Shah, N. S. (2010) · Endocrine Practice · doi:10.4158/ep10031.or · Cited by 72
Posterior Retroperitoneoscopic Adrenalectomy for Clinical and Subclinical Cushing’s Syndrome
Alesina, P. F., Hommeltenberg, S., Meier, B., Petersenn, S., Lahner, H., Schmid, K. W., Mann, K., & Walz, M. K. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0453-0 · Cited by 69
“The diagnosis of CS, performed by several referral endocrinologists, was made on the basis of the results of the available biochemical tests including serum cortisol and plasma ACTH levels, urinary free cortisol, 1 mg overnight or longer low-dose dexamethasone suppression test (DST), together with the presence of clas…”
Metyrapone treatment in Cushing’s syndrome: a real-life study
Ceccato, F., Zilio, M., Barbot, M., Albiger, N. M. E., Antonelli, G., Plebani, M., Watutantrige‐Fernando, S., Sabbadin, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine · doi:10.1007/s12020-018-1675-4 · Cited by 79
Fleseriu, M., Hamrahian, A. H., Hoffman, A. R., Kelly, D. F., & Katznelson, L. (2016) · Endocrine Practice · doi:10.4158/ep161512.dscr · Cited by 68
Pituitary tumors: epidemiology and clinical presentation spectrum
Castro, M. A., Berrocal, V. R., & Corrales, E. P. (2020) · HORMONES · doi:10.1007/s42000-019-00168-8 · Cited by 90
Seppä, S., Kuiri‐Hänninen, T., Holopainen, E., & Voutilainen, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1487 · Cited by 95
Jones, R. L., Owen, L. J., Adaway, J. E., & Keevil, B. G. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.11.036 · Cited by 69
Ronchi, C. L., Sbiera, S., Leich, E., Henzel, K., Rosenwald, A., Allolio, B., & Fassnacht, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073959 · Cited by 68
“Malignancy was defined according to established clinical, biochemical, and morphological criteria [42], while the biochemical diagnosis of cortisol hypersecretion was made according to established guidelines [43].”
MethodUrine Free cortisol in the diagnosis of cushing’s syndrome: Is It worth doing and, If so, how?
Raff, H., Auchus, R. J., Findling, J. W., & Nieman, L. K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3766 · Cited by 68
Self-citationSmith, T. R., Hulou, M. M., Huang, K. T., Nery, B., de Moura, S. M., Coté, D. J., & Laws, E. R. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus14705 · Cited by 69
Second-line tests in the differential diagnosis of ACTH-dependent Cushing’s syndrome
Barbot, M., Trementino, L., Zilio, M., Ceccato, F., Albiger, N. M. E., Daniele, A., Frigo, A. C., Mardari, R., Rolma, G., Boscaro, M., et al. (2016) · Pituitary · doi:10.1007/s11102-016-0729-y · Cited by 70
Approach to patients with pseudo-Cushing’s states
Scaroni, C., Albiger, N. M., Palmieri, S., Iacuaniello, D., Graziadio, C., Damiani, L., Zilio, M., Stigliano, A., Colao, A., Pivonello, R., et al. (2020) · Endocrine Connections · doi:10.1530/ec-19-0435 · Cited by 68
Lengton, R., Schoenmakers, M., Penninx, B. W. J. H., Boon, M. R., & van Rossum, E. F. C. (2024) · Clinical Obesity · doi:10.1111/cob.12725 · Cited by 107
Home waking salivary cortisone to screen for adrenal insufficiency
Debono, M., Elder, C. J., Lewis, J., Fearnside, J., Caunt, S., Dixon, S., Jacques, R. M., Newell-Price, J., Whitaker, M. J., Keevil, B., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200182 · Cited by 66
Self-citationAmlashi, F. G., Swearingen, B., Faje, A. T., Nachtigall, L. B., Miller, K. K., Klibanski, A., Biller, B. M. K., & Tritos, N. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2107 · Cited by 66
Self-citationManaging Cushing’s disease: the state of the art
Colao, A., Boscaro, M., Ferone, D., & Casanueva, F. F. (2014) · Endocrine · doi:10.1007/s12020-013-0129-2 · Cited by 74
Efficacy of medical treatment in Cushing's disease: a systematic review
Gadelha, M. R., & Vieira Neto, L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12345 · Cited by 66
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome
Zilio, M., Mazzai, L., Sartori, M. T., Barbot, M., Ceccato, F., Daidone, V., Casonato, A., Saggiorato, G., Noventa, F., Trementino, L., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0665-z · Cited by 69
Acelajado, M. C., & Calhoun, D. A. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.07.002 · Cited by 77
Anatomy, Physiology, and Laboratory Evaluation of the Pituitary Gland
Hong, G. K., Payne, S. C., & Jane, J. A. (2015) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2015.09.002 · Cited by 74
Is there value in routine screening for Cushing’s syndrome in patients with diabetes?
Mullan, K., Black, N., Thiraviaraj, A., Bell, P. M., Burgess, C., Hunter, S. J., McCance, D. R., Leslie, H., Sheridan, B., & Atkinson, A. B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2453 · Cited by 65
“They currently recommend against widespread testing for Cushing’s syndrome except in patients with adrenal incidentaloma, children with abnormal growth, patients with multiple progressive features suggestive of Cushing’s syndrome, and those with unusual features for their age such as osteoporosis and hypertension (4).”
BackgroundMethodHarmful effects of functional hypercortisolism: a working hypothesis
Tirabassi, G., Boscaro, M., & Arnaldi, G. (2013) · Endocrine · doi:10.1007/s12020-013-0112-y · Cited by 77
“hyperglycemia, hypertension, dyslipidemia, and oligomenorrhea [4–7]) that can be attributed to hypercortisolism; moreover first level tests, like urinary or post-dexamethasone (DST) cortisol are completely ineffective or have suboptimal diagnostic performance [4–7]).”
Delivanis, D. A., Iñiguez‐Ariza, N. M., Zeb, M. H., Moynagh, M. R., Takahashi, N., McKenzie, T. J., Thomas, M. A., Gogos, C., Young, W. F., Bancos, I., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13512 · Cited by 65
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
“The guidelines recommend one of the following biochemical tests for initial CS testing on the basis of its suitability for a given patient: 24 h urinary free cortisol (UFC; at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test (DST), and longer low-d…”
BackgroundMethodInfluentialTrementino, L., Appolloni, G., Ceccoli, L., Marcelli, G., Concettoni, C., Boscaro, M., & Arnaldi, G. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2520-5 · Cited by 89
“The diagnosis of CS and the differential diagnosis between Cushing’s disease (CD), ectopic ACTH secretion (EAS), and adrenal Cushing’s syndrome (ACS) were made on the basis of clinical features and laboratory assessments according to the consensus statement and clinical practice guidelines [3,15].”
MethodChittiboina, P., Montgomery, B. K., Millo, C., Herscovitch, P., & Lonser, R. R. (2015) · Journal of Neurosurgery · doi:10.3171/2014.10.jns14911 · Cited by 64
Castro, M. A., Cancela, A. A., Vior, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.807040 · Cited by 63
Subclinical Cushing’s syndrome
Leo, M. D., Cozzolino, A., Colao, A. A. L., & Pivonello, R. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.02.001 · Cited by 71
Woodmansee, W. W., Carmichael, J. D., Kelly, D. F., & Katznelson, L. J. (2015) · Endocrine Practice · doi:10.4158/ep14541.dscr · Cited by 69
Velikanova, L. I., Shafigullina, Z. R., Lisitsin, A. A., Vorokhobina, N. V., Grigoryan, K., Kukhianidze, E. A., Strelnikova, E. G., Krivokhizhina, N. S., Krasnov, L. M., Fedorov, E. A., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0267-0 · Cited by 62
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?
On behalf of ABC Group, Scillitani, A., Mazziotti, G., Di Somma, C., Moretti, S., Stigliano, A., Pivonello, R., Giustina, A., & Colao, A. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2588-y · Cited by 62
Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman
Hirschberg, A. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac673 · Cited by 73
Nieman, L. K., Castinetti, F., Newell-Price, J. D. C., Valassi, E., Drouin, J., Takahashi, Y., & Lacroix, A. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00588-w · Cited by 88
Self-citationRole of glucocorticoid receptor polymorphism in adrenal incidentalomas
Morelli, V., Donadio, F., Eller‐Vainicher, C., Cirello, V., Olgiati, L., Savoca, C., Cairoli, E., Salcuni, A. S., Beck‐Peccoz, P., & Chiodini, I. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02330.x · Cited by 62
Castinetti, F., Morange, I., Conte‐Devolx, B., & Brue, T. C. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-41 · Cited by 86
“We will not detail precisely all methods and tests proposed to confirm a diagnosis of hypercortisolism (or Cushing’s syndrome, CS): these criteria have been widely described in recent consensus conferences[6,24].”
BackgroundMethodGlucose metabolism in patients with subclinical Cushing’s syndrome
Giordano, R., Guaraldi, F., Berardelli, R., Karamouzis, I., D’Angelo, V., Marinazzo, E., Picu, A., Ghigo, E., & Arvat, E. (2012) · Endocrine · doi:10.1007/s12020-012-9628-9 · Cited by 70
The risks of overlooking the diagnosis of secreting pituitary adenomas
Brue, T. C., & Castinetti, F. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0516-x · Cited by 74
“overnight dexamethasone suppression test [125].”
Perogamvros, I., Owen, L. J., Keevil, B. G., Brabant, G., & Trainer, P. J. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03582.x · Cited by 61
Tabarin, A., Assié, G., Barat, P., Bonnet, F., Bonneville, J. F., Borson-Chazot, F., Bouligand, J., Boulin, A., Brue, T., Caron, P., et al. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.02.001 · Cited by 59
Vassilatou (2014) · doi:10.1530/eje-13-0848 · Cited by 61
Earlier post-operative hypocortisolemia may predict durable remission from Cushing’s disease
Ironside, N. T., Chatain, G. P., Asuzu, D. T., Benzo, S., Lodish, M. B., Sharma, S. T., Nieman, L. K., Stratakis, C. A., Lonser, R. R., & Chittiboina, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0873 · Cited by 65
Self-citationStigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Casa, S. D., Loli, P., Luconi, M., Mantero, F., & Terzolo, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0349-9 · Cited by 63
“A review of the screening tests in overt hypercortisolism is beyond the scope of this Position Statement, and the reader is referred to the Endocrine Society Clinical Practice Guidelines [7].”
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.